Modeling the impact of peginterferon alfa-2a (40KD) (Pegasys®) plus ribavirin therapy on life expectancy and medical care costs in chronic hepatitis C.

被引：0
|
作者：
Jensen, CDM
Bernstein, DE
Hassanein, TI
Foster, GR
Lee, SS
Cheinquer, H
Craxi, A
Cooksley, WGE
Klaskala, W
Green, J
机构：
[1] Rush Presbyterian St Lukes Med Ctr, Chicago, IL 60612 USA
[2] N Shore Univ Hosp, Manhasset, NY USA
[3] Univ Calif San Diego, San Diego, CA 92103 USA
[4] Univ London Imperial Coll Sci Technol & Med, London, England
[5] Univ Calgary, Calgary, AB, Canada
[6] Univ Fed Rio Grande Sul, Hosp Clin Porto Alegre, Porto Alegre, RS, Brazil
[7] Inst Clin Med Policlin, Palermo, Italy
[8] Royal Brisbane Hosp, Brisbane, Qld 4029, Australia
[9] Hoffmann La Roche Inc, Nutley, NJ 07110 USA
来源：
HEPATOLOGY | 2002年 / 36卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1761
引用
收藏
页码：603A / 603A
页数：1
相关论文
共 50 条
  • [31] The safety, efficacy and pharmacokinetics of peginterferon alfa-2a (40KD) in children with chronic hepatitis C
    Schwarz, KB
    Mohan, P
    Narkewicz, M
    Molleston, JP
    Te, HS
    Hu, S
    Sheridan, S
    Lamb, M
    Pappas, SC
    Harb, G
    GASTROENTEROLOGY, 2003, 124 (04) : A700 - A700
  • [32] PEG-IFN alfa-2a (40KD) (PEGASYS®) plus amantadine (AMA) or ribavirin (RBV) in naive patients with chronic hepatitis C (CHC).
    Ideo, G
    Antonucci, G
    Attili, AF
    Babudieri, S
    Chirianni, A
    Craxì, A
    Di Perri, G
    Francavilla, A
    Mangia, A
    Picciotto, A
    Rizzetto, M
    Ruggiero, G
    Suter, F
    Tripi, S
    Sarracino, M
    HEPATOLOGY, 2003, 38 (04) : 728A - 728A
  • [33] PEG-IFN alfa-2a (40KD) (Pegasys) plus amantadine (AMA) or ribavirin (RBV) in naive patients with chronic hepatitis C (CHC)
    Ideo, G
    Attili, A
    Ruggiero, G
    Craxi, A
    Di Perri, G
    Mangia, A
    Picciotto, A
    Rizzetto, M
    Suter, F
    Sarracino, M
    JOURNAL OF HEPATOLOGY, 2003, 38 : 146 - 146
  • [34] Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin
    Reau, Nancy
    Hadziyannis, Stephanos J.
    Messinger, Diethelm
    Fried, Michael W.
    Jensen, Donald M.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 (08): : 1981 - 1988
  • [35] Peginterferon alfa-2a (Pegasys) for chronic hepatitis C
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2003, 45 (1151): : 19 - 20
  • [36] Sustained virological and biochemical responses to peginterferon alfa-2a (40KD) (Pegasys®) plus ribavirin (Copegus®) in patients with chronic hepatitis C (CHC) and compensated cirrhosis/bridging fibrosis.
    Marcellin, P
    Roberts, S
    Alberti, A
    Trepo, C
    Zeuzem, S
    Sette, H
    Brouwer, JT
    HEPATOLOGY, 2004, 40 (04) : 394A - 394A
  • [37] Pharmacokinetics, pharmacodynamics and antiviral response in patients with chronic hepatitis C infection on methadone maintenance therapy receiving peginterferon (40KD) alfa-2a (Pegasys®)
    Sulkowski, MS
    Rossi, SJ
    Arora, S
    Yalamanchili, S
    Lamb, MW
    GASTROENTEROLOGY, 2003, 124 (04) : A702 - A703
  • [38] Impact of baseline hepatitis C virus (HCV) RNA and genotype on the efficacy of peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in patients with compensated cirrhosis/bridging fibrosis
    Marcellin, P
    Roberts, S
    Alberti, A
    Trepo, C
    Zeuzem, S
    Sette, H
    Brouwer, JT
    Horta-Vale, A
    Gane, E
    HEPATOLOGY, 2005, 42 (04) : 672A - 672A
  • [39] Efficacy and safety of 22 weeks of maintenance therapy with peginterferon alfa-2a(40KD)(pegasys)alone versus peginterferon alfa-2a plus ribavirin in naive, patients with chronic hepatitis c and genotype I who respond to a 24 week course therapy of peginterferon alfa-2a plus ribavirin: Preliminary results of an open, multicenter randomized trial.
    Bronowicki, JP
    Ouzan, D
    Asselah, T
    Desmorat, H
    Zarski, JP
    Couzigou, P
    Bourliere, M
    Renou, C
    Tran, A
    Melin, P
    Hezode, C
    Bouvier, M
    Lonjon-Domanec, I
    Neuilly, R
    Pawlotsky, JM
    HEPATOLOGY, 2002, 36 (04) : 293A - 293A
  • [40] Effect of hepatic steatosis in patients with chronic hepatitis C virus genotype 2 or 3 treated with peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) for 16 or 24 weeks
    Rodriguez-Torres, Maribel
    Govindarajan, Sugantha
    Shafran, Stephen
    Morgan, Timothy
    Anand, Bhupinder S.
    Barange, Karl
    Suter, Fredy
    Lin, Amy
    Hooper, Gregory
    Zeuzem, Stefan
    Shiffman, Mitchell
    HEPATOLOGY, 2006, 44 (04) : 333A - 333A
12345